title: A randomized, double-masked study on the treatment of retinal vein occlusion with troxerutin.
abstract: Hemorheologic factors probably play a role in the pathogenesis and prognosis of retinal vein occlusion. Accordingly, we designed a prospective, randomized, double-masked study to evaluate the effect of troxerutin, a rheologic drug, on retinal vein occlusion. Fifty-three patients were included, 27 with central retinal vein occlusion and 26 with branch retinal vein occlusion. They were randomly assigned for treatment with either troxerutin or a placebo. All subjects were similar in age, gender, associated diseases, hemorheologic values, and clinical severity of the retinal vein occlusion. At the end of follow-up, members of the troxerutin-treated group, as compared with the placebo group, showed significant improvement in visual acuity (P = .03), macular threshold (P = .01), retinal circulation times (P = .04), and macular edema (P = .05). Furthermore, they had diminished progression of ischemia (P = .05) and decreased red blood cell aggregability (P = .006) when compared with the controls. These encouraging preliminary results obtained with a rheologic treatment attest to the pathogenic role of blood viscosity in retinal vein occlusion and suggest that a large-scale randomized study should be conducted.
authors.affiliation: University Eye Clinic of Ophthalmology, Créteil, France.
authors.forename: A
authors.initials: A
authors.lastname: Glacet-Bernard
authors.forename: G
authors.initials: G
authors.lastname: Coscas
authors.forename: A
authors.initials: A
authors.lastname: Chabanel
authors.forename: A
authors.initials: A
authors.lastname: Zourdani
authors.forename: F
authors.initials: F
authors.lastname: Lelong
authors.forename: M M
authors.initials: MM
authors.lastname: Samama
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000925:Anticoagulants / Q000627:therapeutic use*; D004311:Double-Blind Method; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D006896:Hydroxyethylrutoside / Q000031:analogs & derivatives* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D012170:Retinal Vein Occlusion / Q000188:drug therapy* / Q000503:physiopathology; D012171:Retinal Vessels / Q000502:physiology; D016896:Treatment Outcome; D014792:Visual Acuity
chemical_list: D000925:Anticoagulants; D006896:Hydroxyethylrutoside; C005865:troxerutin